Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

COVID-19 and kidney disease: insights from epidemiology to inform clinical practice

“…Although the trial included CKD in its definition of ‘high-risk’, patients with eGFR <60 ml/min/1.73 m 2 comprised <1% of participants 126 . The RECOVERY trial found that combination casirivimab–imdevimab monoclonal antibody therapy reduced mortality in seronegative patients hospitalized with COVID-19; participants included those on dialysis and kidney transplant recipients 127 . A living systematic review and network meta-analysis (including 47 randomized controlled trials published up to 21 July 2021) concluded that casirivimab–imdevimab and some other antibody therapies may reduce hospitalization in patients with non-severe COVID-19, whereas convalescent plasma, intravenous immunoglobulin and other antibody and cellular therapies are unlikely to provide meaningful benefit, although most of the studies included in the analysis did not seem to include patients with kidney diseases 128 .…”

Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis

“…However, this EUA was later revoked in favor of mAb cocktails (such as bamlanivimab and etesevimab or casirivimab and imdevimab) due to concerns regarding the possibility of antigen escape [ 14 ]. Recent RCTs, such as the RECOVERY and BLAZE-1 trials, have associated the use of mAb combination therapies with reduced mortality, viral load, and COVID-related hospitalizations [ 15 – 17 ]; however, the efficacy and safety of mAb therapies has yet to be demonstrated in large, diverse patient populations. In addition to mAbs, multiple candidate animal-based polyclonal antibody therapies are also under active investigation for the treatment of COVID-19 [ 18 , 19 ].…”

Treatment with anti-SARS-CoV-2 monoclonal antibodies in pregnant and postpartum women: first experiences in Florence, Italy

“…Moreover, the use of mAbs does not exclude the use of other drugs currently employed as standard treatment for COVID-19. Some patients in our cohort were treated with steroids due to the presence of pneumonia and hypoxia, like in the RECOVERY trial arms that tested the use of casirivimab/imdevimab 8 gr on inpatients [ 12 ].…”

“…At first, these were used only in outpatients with mild to moderate COVID-19, with risk factors for developing severe disease, and within 10 days from symptoms onset [ 11 ]. Then, recent data has shown a potential benefit in inpatients hospitalized for COVID-19 [ 12 ]. For this reason, since August 2021, in Italy the Agenzia Italiana del Farmaco (AIFA) has authorized the use of a higher dose of mAbs (casirivimab/imdevimab 8 g) in hospitalized seronegative patients with COVID-19, not requiring high flow oxygen or mechanical ventilation [ 13 ].…”